Duloxetine: A new approach for treating stress urinary incontinence

International Journal of Gynecology and Obstetrics

Volumn 86, Issue SUPPL., 2004, Pages

  Moore, Kate ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Duloxetine; Pharmacological therapy; Randomized controlled trials; Review; Stress urinary incontinence

Indexed keywords

DULOXETINE; NORADRENALIN UPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR;

ADULT; AFRICA; AGED; ARTICLE; AUSTRALIA; BLADDER CAPACITY; BLADDER IRRITATION; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; EUROPE; FATIGUE; FEMALE; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MICTURITION; MULTICENTER STUDY; NAUSEA; NORTH AMERICA; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SOUTH AMERICA; STRESS INCONTINENCE; XEROSTOMIA;

EID: 4043082708     PISSN: 00207292     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijgo.2004.05.009     Document Type: Article

References (24)

1. Hannestad Y.S., Rortveit G., Sandvik H., Hunskaar S. A community-based epidemiological survey of female urinary incontinence: the Norwegian EPINCONT study. J Clin Epidemiol. 53:2000;1150-1157
2. Minassian V.A., Drutz H.P., Al-Badr A. Urinary incontinence as a worldwide problem. Int J Gynecol Obstet. 82:2003;327-338
3. Bø K., Talseth T., Holme I. Single blind, randomised controlled trial of pelvic floor exercises, electrical stimulation, vaginal cones, and no treatment in management of genuine stress incontinence in women. Br Med J. 318:1999;487-493
4. Viktrup L., Bump R.C. Pharmacological agents used for the treatment of stress urinary incontinence in women. Curr Med Res Opin. 19:2003;485-490
5. Bymaster F.P., Dreshfield-Ahmad L.J., Threlkeld P.G., Shaw J.L., Thompson L., Nelson D.L., et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepineprine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacol. 25:2001;871-880
6. Thor K.B., Katofiasc M.A. Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anesthetized female cat. J Pharmacol Exp Ther. 274:1995;1014-1024
7. Thor K. Targeting serotonin and noradrenaline receptors in stress urinary incontinence. Int J Gynecol Obstet 2004;86(Suppl 1):S41-S55
8. Norton PA, Zinner NR, Yalcin I, Bump RC, for the Duloxetine Urinary Incontinence Study Group. Duloxetine vs. placebo in the treatment of stress urinary incontinence. Am J Obstet Gynecol 2002;187:40-48
9. Dmochowski RR, Miklos JR, Norton PA, Zinner NR, Yalcin I, Bump RC, for the Duloxetine Urinary Incontinence Study Group. Duloxetine vs. placebo for the treatment of North American women with stress urinary incontinence. J Urol 2003;170:1259-1263
10. Van Kerrebroeck P., Abrams P., Lange R., Slach M., Wyndaele J.-J., Yalcin I., et al. Duloxetine vs. placebo in the treatment of European and Canadian women with stress urinary incontinence. Br J Obstet Gynecol. 111:2004;249-257
11. Millard RJ, Moore K, Rencken R, Yalcin I, Bump RC, for the Duloxetine UI Study Group. Duloxetine vs. placebo in the treatment of stress urinary incontinence: a four-continent randomized clinical trial, BJU Int 2004;93:311-318
12. Wagner T.H., Patrick D.L., Bavendam T.G., Martin M.L., Buesching D.P. Quality of life of persons with urinary incontinence: development of a new measure. Urology. 47:1996;67-71
13. Patrick D.L., Martin M.L., Bushnell D.M., Yalcin I., Wagner T.H., Buesching D.P. Quality of life of women with urinary incontinence: further development of the incontinence quality of life instrument (I-QOL). Urology. 53:1999;71-76
14. Donovan J.L., Badia X., Corcos J., Kellener C., Naughton M., et al. Symptom and quality of life assessment. Abrams P., Cardozo L., Khoury S., Wein A. Incontinence. Second ed:2002;267-316 Health Publication Ltd, Plymouth, UK
15. Guy W. EGDEU assessment manual for psychopharmacology. 1976;218-222 National Institute of Mental Health, US Department of Health, Education, and Welfare, Rockville (MD)
16. Yalcin I., Bump R.C. Validation of two global impression questionnaires for incontinence. Am J Obstet Gynecol. 189:2003;98-101
17. Drutz H.P., Cardozo L., Baygani S.K., Bump R.C. Duloxetine treatment of women with pure urodynamic stress incontinence awaiting continence surgery. Int J Gynecol Obstet. 83:(Suppl 3):2003;34. abs. FC2.7.2
18. Cardozo L., Drutz H.P., Baygani S.K., Bump R.C. Duloxetine response and onset of action in women with severe stress urinary incontinence (SUI) awaiting continence surgery. Int J Gynecol Obstet. 83:(Suppl 3):2003;34. abs. FC2.7.3
19. Moore K.H., Hay D., Imrie A., Watson A., Goldstein M. Oxybutynin hydrochloride (3 mg) in the treatment of women with idiopathic detrusor instability. Br J Urol. 66:1990;479-485
20. Dubeau CE, Khullar V. Drug impact on the SUI component of mixed incontinence: is its all placebo effect? Presented at the 2002 American Urogynecologic Society Meeting, San Francisco
21. Ramsay I.N., Thou M. A randomised, double-blind, placebo controlled trial of pelvic floor exercises in the treatment of genuine stress incontinence. Neurourol Urodyn. 9:1990;398-399
22. Yalcin I., Bump R. The effect of prior treatment experience and incontinence severity on the placebo response of stress urinary incontinence. Neurourol Urodyn. 22:2003;481-482. abs. 83
23. Moore K.H., O'Sullivan R.J., Simons A., Prashar S., Anderson P., Louey M. Randomised controlled trial of nurse continence advisor therapy compared with standard urogynaecology regimen for conservative incontinence treatment: efficacy, costs and two year follow up. Br J Obs Gynaecol. 110:2003;649-657
24. Beck A., Steer R.A., Brown G.K. Manual for the Beck Depression Inventory-II. 1996;Psychological Corp, San Antonio, Texas